Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Rationale: Recent clinical trial successes have created an urgent need for earlier and more sensitive endpoints of disease progression in idiopathic pulmonary fibrosis (IPF). Domiciliary spirometry permits more frequent measurement of FVC than does hospital-based assessment, which therefore affords the opportunity for a more granular insight into changes in IPF progression. Objectives: To determine the feasibility and reliability of measuring daily FVC in individuals with IPF. Methods: Subjects with IPF were given handheld spirometers and instruction on how to self-administer spirometry. Subjects recorded daily FEV1 and FVC for up to 490 days. Clinical assessment and hospital-based spirometry was undertaken at 6 and 12 months, and outcome data were collected for 3 years. Measurements and Main Results: Daily spirometry was recorded by 50 subjects for a median period of 279 days (range, 13–490 d). There were 18 deaths during the active study period. Home spirometry showed excellent correlation with hospital-obtained readings. The rate of decline in FVC was highly predictive of outcome and subsequent mortality when measured at 3 months (hazard ratio [HR], 1.040; 95% confidence interval [CI], 1.021–1.062; P ≤ 0.001), 6 months (HR, 1.024; 95% CI, 1.014–1.033; P < 0.001), and 12 months (HR, 1.012; 95% CI, 1.007–1.016; P = 0.001). Conclusions: Measurement of daily home spirometry in patients with IPF is highly clinically informative and is feasible to perform for most of these patients. The relationship between mortality and rate of change of FVC at 3 months suggests that daily FVC may be of value as a primary endpoint in short proof-of-concept IPF studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is noteworthy that hospital-based FVC measurements, compared with unsupervised daily home measurements, have been suggested to be less sensitive in detecting progression of fibrosis and in predicting subsequent prognosis [19].”
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 3×
“This gradual decline is punctuated by unheralded, rapid-onset, catastrophic, acute exacerbations in approximately 5 to 8% of patients with IPF per year (2).”
BackgroundResultAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationWells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Landmark Analysis at the 25-Year Landmark Point
Dafni, U. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957951 · Cited by 569 · cited 1×
“By contrast, a landmark analysis (18) of the 12-month rate of change in home-measured FVC (Figure 6B) for those subjects still alive at 12 months demonstrated that a 12-month rate of change of .”
ResultThe role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis
Molyneaux, P. L., Cox, M. J., Willis-Owen, S. A. G., Mallia, P., Russell, K. E., Russell, A.-M., Murphy, E., Johnston, S. L., Schwartz, D. A., Wells, A. U., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0541oc · Cited by 567 · cited 1×
“spirometry may also have a role in the early detection of infection or acute exacerbations (24).”
BackgroundSelf-citationdu Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527 · cited 2×
“Predicting Subsequent Outcome Categorical change in FVC over 12 months in individuals with IPF has previously been demonstrated to predict subsequent survival in several retrospective studies (6, 8, 16).”
BackgroundSelf-citationAscertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
du Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Raghu, G., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1790oc · Cited by 424
Zappala, C. J., Latsi, P. I., Nicholson, A. G., Colby, T. V., Cramer, D., Renzoni, E. A., Hansell, D. M., du Bois, R. M., & Wells, A. U. (2010) · European Respiratory Journal · doi:10.1183/09031936.00155108 · Cited by 372 · cited 2×
“Predicting Subsequent Outcome Categorical change in FVC over 12 months in individuals with IPF has previously been demonstrated to predict subsequent survival in several retrospective studies (6, 8, 16).”
BackgroundSelf-citationIdiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Maher, T. M., Wells, A. U., & Laurent, G. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00069307 · Cited by 341 · cited 1×
“Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease of unknown etiology (1).”
BackgroundSelf-citationForced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib
Karimi-Shah, B. A., & Chowdhury, B. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500526 · Cited by 316
Jenkins, R. G., Simpson, J. K., Saini, G., Bentley, J. H., Russell, A.-M., Braybrooke, R., Molyneaux, P. L., McKeever, T. M., Wells, A. U., Flynn, A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00048-x · Cited by 314 · cited 1×
“Study Subjects Subjects with a consensus diagnosis of IPF [made in accordance with current international criteria (13)] were recruited as a subgroup of the PROFILE (Prospective Observation of Fibrosis in the Lung Clinical Endpoints) study (14), from the interstitial lung disease unit at Royal Brompton Hospital, London.”
MethodSelf-citationdu Bois, R. M., Albera, C., Bradford, W. Z., Costabel, U., Leff, J. A., Noble, P. W., Sahn, S. A., Valeyre, D., Weycker, D., & King, T. E. (2014) · European Respiratory Journal · doi:10.1183/09031936.00131813 · Cited by 246
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
Richeldi, L., Ryerson, C. J., Lee, J. S., Wolters, P. J., Koth, L. L., Ley, B., Elicker, B. M., Jones, K. D., King, T. E., Ryu, J. H., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201184 · Cited by 185 · cited 2×
“Predicting Subsequent Outcome Categorical change in FVC over 12 months in individuals with IPF has previously been demonstrated to predict subsequent survival in several retrospective studies (6, 8, 16).”
Backgrounddu Bois, R. M., Nathan, S. D., Richeldi, L., Schwarz, M. I., & Noble, P. W. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1010pp · Cited by 95 · cited 1×
“This endpoint is judged to be both clinically meaningful and important to patients (17).”
BackgroundPirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Aravena, C., Gonzalo Labarca, T., Venegas, C., Arenas, Á., & Rada, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136160 · Cited by 84
Rozas, C. J. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.142.7.1287 · Cited by 70
Longitudinal Forced Vital Capacity Monitoring as a Prognostic Adjunct after Lung Transplantation
Belloli, E. A., Wang, X., Murray, S., Forrester, G., Weyhing, A., Lin, J., Ojo, T., & Lama, V. N. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201501-0174oc · Cited by 62 · cited 1×
“Within respiratory medicine, home disease monitoring in the form of peak flow measurement is already a feature of asthma self-management, and in lung transplantation recipients, daily surveillance spirometry is used for the detection of episodes of acute rejection (11).”
BackgroundRozas, C. J. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.1982.00340200045012 · Cited by 59 · cited 1×
“Furthermore, the variability seen in day-to-day readings obtained by the same subject was comparable to that observed in reproducibility studies performed with hospital-based spirometry in both healthy individuals and those with chronic obstructive pulmonary disease (10).”
ResultCorrection: Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Aravena, C., Gonzalo Labarca, T., Venegas, C., Arenas, Á., & Gabriel Rada, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140288 · Cited by 24
Daily Hand-Held Spirometry For The Monitoring Of Patients With Idiopathic Pulmonary Fibrosis
Russell, A., Molyneaux, P. L., Lukey, P. T., Fraser, U. H., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2012) · doi:10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4579 · Cited by 3 · cited 1×
“Some of the results of this study have been previously reported in the form of an abstract (12).”
ResultSelf-citation
Cited by
Graham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., Hallstrand, T. S., Kaminsky, D. A., McCarthy, K., McCormack, M. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1590st · Cited by 4,305
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
Self-citationGrunewald, J., Grutters, J. C., Arkema, E. V., Saketkoo, L. A., Moller, D. R., & Müller-Quernheim, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0096-x · Cited by 479
Interstitial Lung Disease: A Review
Maher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 388
Self-citationFibrosing interstitial lung diseases: knowns and unknowns
Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0100-2018 · Cited by 336
Metadata
- Authors
- Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M.
- Affiliations
- National Institute for Health and Care Research (GB)
- Southmead Hospital (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Maher, Toby M.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10
- Volume
- 194
- Issue
- 8
- Pages
- 989-997
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC5067818
- OpenAlex
- W2336917368
- Cited by
- 178
- References
- 26
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 20 · 2023: 18 · 2022: 23 · 2021: 22 · 2020: 17 · 2019: 22 · 2018: 17 · 2017: 15 · 2016: 4
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (CDA13-017)
- Royal Brompton and Harefield NHS Foundation Trust
- National Institute for Health and Care Research (PB-PG-0712-28073, CS-2013-13-017, CDRF-2012-03-053)
- Imperial College London
- Versus Arthritis (20719)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, home spirometry, disease progression, mortality prediction, primary endpoint
- MeSH terms
- Aged, Female, Humans, Male, Self Care, Spirometry, Time Factors, Vital Capacity, Proportional Hazards Models, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.